Clinical Trials Logo

Clinical Trial Summary

Overgrowth syndromes are rare genetic disorders defined by tissue hypertrophy that can be either localized or generalized, affecting both latitudinal and longitudinal growth. The genes involved in overgrowth syndromes are not well characterized but mostly concern the PIK3CA/AKT/mTOR pathway, a major actor of cell growth and proliferation. The mutations are not inherited but occurs during embryogenesis leading to somatic mosaicism. Owing to the variability of the clinical presentation, their exact prevalence is yet unknown. In order to answer this question, the investigators team create here the first French national registry on overgrowth syndromes.


Clinical Trial Description

Overgrowth syndromes are rare genetic disorders defined by tissue hypertrophy that can be either localized or generalized, affecting both latitudinal and longitudinal growth. The genes involved in overgrowth syndromes are not well characterized but mostly concern the PIK3CA/AKT/mTOR pathway, a major actor of cell growth and proliferation. The mutations are not inherited but occurs during embryogenesis leading to somatic mosaicism. Owing to the variability of the clinical presentation, their exact prevalence is yet unknown. In order to answer this question, the investigators team create here the first French national registry on overgrowth syndromes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05563831
Study type Observational
Source Institut National de la Santé Et de la Recherche Médicale, France
Contact Guillaume GC Canaud, MD,PHD
Phone 0140615425
Email guillaume.canaud@inserm.fr
Status Recruiting
Phase
Start date February 21, 2023
Completion date December 31, 2028

See also
  Status Clinical Trial Phase
Completed NCT02561182 - Bone Health in Patients With Overgrowth
Completed NCT02384122 - Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias Phase 3
Active, not recruiting NCT03987152 - Treatment of Congenital Vascular Malformations Using Sirolimus: Improving Quality of Life Phase 3
Recruiting NCT05113420 - The Efficacy and Safety of Different Phlebotonic Drugs in Children With Venous Malformations
Recruiting NCT06189092 - Treatment of Low-flow Venous Malformations With Electrosclerotherapy. Prospective Observational Study
Completed NCT04637997 - Influence of Flat-knitted Compression Stockings Class I and II on Venous Malformations N/A
Recruiting NCT02883023 - Electrosclerotherapy for Capillary Malformations Phase 2
Recruiting NCT06160739 - Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations
Completed NCT02991352 - Stereotactic MRI Based Image Guidance for the Treatment of Vascular Malformations - a Pilot Study N/A
Recruiting NCT03972592 - Topical Sirolimus in Cutaneous Lymphatic Malformations Phase 2
Active, not recruiting NCT05418816 - SelfWrap-Assisted Arteriovenous Fistulas N/A
Recruiting NCT04104464 - Patient Reported Outcomes for Vascular Malformations EmbolizatioN (PROVEN)
Recruiting NCT02638389 - Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care Phase 3
Recruiting NCT03440827 - Development of a Specific Scale of Life'Quality for Children With Low-flow Vascular Malformations N/A
Completed NCT00577213 - Diagnosis of Hemangiomas and Vascular Malformations N/A
Recruiting NCT05494710 - Bleomycin Electrosclerotherapy Treatment of Vascular Malformations: A Feasibility Study N/A
Completed NCT01576601 - The Management of Postoperative Craniotomy Pain in Pediatric Patients N/A
Completed NCT04836884 - Vascular Anomaly Pathology and Genomics Biopsy Study N/A
Not yet recruiting NCT05983159 - A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations Phase 2